List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1668572/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet, The, 2003, 362, 7-13.	6.3	1,664
2	Truncations of Titin Causing Dilated Cardiomyopathy. New England Journal of Medicine, 2012, 366, 619-628.	13.9	1,147
3	Mutations in Cypher/ZASPin patients with dilated cardiomyopathy and left ventricular non-compaction. Journal of the American College of Cardiology, 2003, 42, 2014-2027.	1.2	479
4	Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by doppler echocardiography: Clinical, echocardiographic and hemodynamic correlations and prognostic implications. Journal of the American College of Cardiology, 1993, 22, 808-815.	1.2	421
5	Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. Journal of the American College of Cardiology, 2003, 41, 771-780.	1.2	411
6	Prevalence and Prognostic Significance of Left Ventricular Reverse Remodeling in Dilated Cardiomyopathy Receiving Tailored Medical Treatment. Journal of the American College of Cardiology, 2011, 57, 1468-1476.	1.2	337
7	Familial dilated cardiomyopathy. Journal of the American College of Cardiology, 1999, 34, 181-190.	1.2	304
8	Electrocardiography of myocarditis revisited: Clinical and prognostic significance of electrocardiographic changes. American Heart Journal, 1992, 124, 455-467.	1.2	227
9	Persistence of Restrictive Left Ventricular Filling Pattern in Dilated Cardiomyopathy: An Ominous Prognostic Sign. Journal of the American College of Cardiology, 1997, 29, 604-612.	1.2	225
10	α-Myosin Heavy Chain. Circulation, 2005, 112, 54-59.	1.6	204
11	The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. European Heart Journal, 2006, 27, 1440-1446.	1.0	201
12	SCN5A Mutations Associate With Arrhythmic Dilated Cardiomyopathy and Commonly Localize to the Voltage-Sensing Mechanism. Journal of the American College of Cardiology, 2011, 57, 2160-2168.	1.2	197
13	Left ventricular involvement in right ventricular dysplasia. American Heart Journal, 1992, 123, 711-724.	1.2	185
14	Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: A multiparametric approach to heart failure prognosis. International Journal of Cardiology, 2013, 167, 2710-2718.	0.8	183
15	Longâ€ŧerm prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years. European Journal of Heart Failure, 2014, 16, 317-324.	2.9	177
16	Prevalence of Desmin Mutations in Dilated Cardiomyopathy. Circulation, 2007, 115, 1244-1251.	1.6	176
17	Multicenter Prospective Observational Study on Acute and Chronic Heart Failure. Circulation: Heart Failure, 2013, 6, 473-481.	1.6	170
18	Thymopoietin (lamina-associated polypeptide 2) gene mutation associated with dilated cardiomyopathy. Human Mutation, 2005, 26, 566-574.	1.1	167

#	Article	IF	CITATIONS
19	Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: Data from a large nationwide cardiology database (IN-CHF Registry). American Heart Journal, 2002, 143, 45-55.	1.2	162
20	Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. European Heart Journal, 2005, 26, 2259-2268.	1.0	154
21	Long-Term Evolution and Prognostic Stratification of Biopsy-Proven Active Myocarditis. Circulation, 2013, 128, 2384-2394.	1.6	152
22	Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart, 2007, 93, 968-973.	1.2	135
23	Prevalence and prognostic impact of nonâ€cardiac coâ€morbidities in heart failure outpatients with preserved and reduced ejection fraction: a communityâ€based study. European Journal of Heart Failure, 2018, 20, 1257-1266.	2.9	130
24	Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. Journal of the American College of Cardiology, 1999, 33, 1926-1934.	1.2	122
25	Prognostic predictors in arrhythmogenic right ventricular cardiomyopathy: results from a 10-year registry. European Heart Journal, 2011, 32, 1105-1113.	1.0	121
26	Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale of two worlds—the TEMISTOCLE study. American Heart Journal, 2003, 146, 735.	1.2	115
27	Acute heart failure patient profiles, management and inâ€hospital outcome: results of the Italian Registry on Heart Failure Outcome. European Journal of Heart Failure, 2012, 14, 1208-1217.	2.9	112
28	Predicting heart failure outcome from cardiac and comorbid conditions: The 3C-HF score. International Journal of Cardiology, 2013, 163, 206-211.	0.8	108
29	Arrhythmogenic Phenotype in Dilated Cardiomyopathy: Natural History and Predictors of Lifeâ€Threatening Arrhythmias. Journal of the American Heart Association, 2015, 4, e002149.	1.6	102
30	Antiâ€remodelling effect of canrenone in patients with mild chronic heart failure (AREA INâ€CHF study): final results. European Journal of Heart Failure, 2009, 11, 68-76.	2.9	99
31	In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs.) Tj ETQq1 Cardiology, 2014, 173, 163-169.	l 0.78431 0.8	4 rgBT /Over 98
32	Incremental Value of Gait Speed in Predicting Prognosis of Older Adults WithÂHeart Failure. JACC: Heart Failure, 2016, 4, 289-298.	1.9	93
33	The Prognostic Impact of the Evolution ofÂRV Function in IdiopathicÂDCM. JACC: Cardiovascular Imaging, 2016, 9, 1034-1042.	2.3	92
34	Usefulness of frailty profile for targeting older heart failure patients in disease management programs: a cost-effectiveness, pilot study. Journal of Cardiovascular Medicine, 2010, 11, 739-747.	0.6	87
35	Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. European Journal of Heart Failure, 2007, 9, 901-909.	2.9	85
36	Functional mitral regurgitation predicts 1-year mortality in elderly patients with systolic chronic heart failure. European Journal of Heart Failure, 2005, 7, 1112-1117.	2.9	84

#	Article	IF	CITATIONS
37	Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a longâ€ŧerm comparison. European Journal of Heart Failure, 2018, 20, 700-710.	2.9	84
38	Changes in Early and Late Diastolic Filling Patterns Induced by Long-term Adrenergic Î ² -Blockade in Patients With Idiopathic Dilated Cardiomyopathy. Circulation, 1996, 94, 673-682.	1.6	79
39	Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET. American Heart Journal, 2005, 149, 370-376.	1.2	74
40	Permanent atrial fibrillation affects exercise capacity in chronic heart failure patients. European Heart Journal, 2008, 29, 2367-2372.	1.0	73
41	Persistent Recovery of Normal Left Ventricular Function and Dimension in Idiopathic Dilated Cardiomyopathy During Longâ€Term Followâ€up: Does Real Healing Exist?. Journal of the American Heart Association, 2015, 4, e001504.	1.6	73
42	Clinical and pathologic study of familial dilated cardiomyopathy. American Journal of Cardiology, 1990, 65, 1449-1453.	0.7	72
43	The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: Data from the SHORTWAVE study. Diabetes Research and Clinical Practice, 2013, 101, 309-316.	1.1	72
44	Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. European Journal of Heart Failure, 2002, 4, 321-329.	2.9	69
45	A Comparison of the Effects of Carvedilol and Metoprolol on Well-Being, Morbidity, and Mortality (the "Patient Journeyâ€) in Patients With Heart Failure. Journal of the American College of Cardiology, 2006, 47, 1603-1611.	1.2	66
46	How Can Optimization of Medical Treatment Avoid Unnecessary Implantable Cardioverter-Defibrillator Implantations in Patients With Idiopathic Dilated Cardiomyopathy Presenting With "SCD-HeFT Criteria?― American Journal of Cardiology, 2012, 109, 729-735.	0.7	66
47	Role of Titin Missense Variants in Dilated Cardiomyopathy. Journal of the American Heart Association, 2015, 4, .	1.6	64
48	Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: data from the <scp>MECKI</scp> Score Research Group. European Journal of Heart Failure, 2016, 18, 545-553.	2.9	64
49	Carvedilol Protects Better Against Vascular Events Than Metoprolol in Heart Failure. Journal of the American College of Cardiology, 2007, 49, 963-971.	1.2	62
50	Prognostic Value of Indeterminable Anaerobic Threshold in Heart Failure. Circulation: Heart Failure, 2013, 6, 977-987.	1.6	60
51	Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years. European Journal of Heart Failure, 2019, 21, 208-217.	2.9	60
52	Contemporary survival trends and aetiological characterization in nonâ€ischaemic dilated cardiomyopathy. European Journal of Heart Failure, 2020, 22, 1111-1121.	2.9	54
53	Long-term evolution of right ventricular dysplasia-cardiomyopathy. American Heart Journal, 1995, 129, 412-415.	1.2	53
54	The Safety of Amiodarone in Patients With Heart Failure. Journal of Cardiac Failure, 2007, 13, 340-345.	0.7	52

#	Article	IF	CITATIONS
55	Poor Prognosis of Rare Sarcomeric Gene Variants in Patients with Dilated Cardiomyopathy. Clinical and Translational Science, 2013, 6, 424-428.	1.5	52
56	Early Improvement of Functional Mitral Regurgitation in Patients With Idiopathic Dilated Cardiomyopathy. American Journal of Cardiology, 2015, 115, 1137-1143.	0.7	52
57	Prognostic impact of familial screening in dilated cardiomyopathy. European Journal of Heart Failure, 2010, 12, 922-927.	2.9	51
58	New-onset left bundle branch block independently predicts long-term mortality in patients with idiopathic dilated cardiomyopathy: data from the Trieste Heart Muscle Disease Registry. Europace, 2014, 16, 1450-1459.	0.7	48
59	Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism. Internal and Emergency Medicine, 2018, 13, 475-489.	1.0	48
60	Beta-Blockers in Heart Failure: Are Pharmacological Differences Clinically Important?. Heart Failure Reviews, 2004, 9, 123-130.	1.7	46
61	Are Nonsustained Ventricular Tachycardias Predictive of Major Arrhythmias in Patients with Dilated Cardiomyopathy on Optimal Medical Treatment?. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 290-299.	0.5	46
62	Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer. Internal and Emergency Medicine, 2012, 7, 439-446.	1.0	45
63	Cardiovascular mortality and chronotropic incompetence in systolic heart failure: the importance of a reappraisal of current cutâ€off criteria. European Journal of Heart Failure, 2014, 16, 201-209.	2.9	44
64	Dobutamine echocardiography in idiopathic dilated cardiomyopathy: clinical and prognostic implications. European Journal of Heart Failure, 2002, 4, 49-61.	2.9	43
65	Natural history of dilated cardiomyopathy: from asymptomatic left ventricular dysfunction to heart failure – a subgroup analysis from the Trieste Cardiomyopathy Registry. Journal of Cardiovascular Medicine, 2009, 10, 699-705.	0.6	41
66	Natural History of Dilated Cardiomyopathy in Children. Journal of the American Heart Association, 2016, 5, .	1.6	39
67	Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. European Journal of Heart Failure, 2007, 9, 1128-1135.	2.9	36
68	The metabolic exercise test data combined with Cardiac And Kidney Indexes (MECKI) score and prognosis in heart failure. A validation study. International Journal of Cardiology, 2016, 203, 1067-1072.	0.8	36
69	Heart failure and anemia: Effects on prognostic variables. European Journal of Internal Medicine, 2017, 37, 56-63.	1.0	33
70	Potential risk of β-blockade withdrawal in congestive heart failure due to abrupt autonomic changes. International Journal of Cardiology, 1999, 68, 171-177.	0.8	32
71	The 30â€day metric in acute heart failure revisited: data from <scp>INâ€HF</scp> Outcome, an Italian nationwide cardiology registry. European Journal of Heart Failure, 2015, 17, 1032-1041.	2.9	32
72	Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation. European Journal of Preventive Cardiology, 2015, 22, 1046-1055.	0.8	32

#	Article	IF	CITATIONS
73	Prognostic Value of Echocardiographic Calcium Score in Patients With a Clinical Indication for Stress Echocardiography. JACC: Cardiovascular Imaging, 2015, 8, 389-396.	2.3	31
74	Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). European Journal of Internal Medicine, 2021, 85, 1-13.	1.0	31
75	Prognostic value of cardiopulmonary exercise testing in Idiopathic Dilated Cardiomyopathy. International Journal of Cardiology, 2016, 223, 596-603.	0.8	30
76	The future of telemedicine for the management of heart failure patients: a Consensus Document of the Italian Association of Hospital Cardiologists (A.N.M.C.O), the Italian Society of Cardiology (S.I.C.) and the Italian Society for Telemedicine and eHealth (Digital S.I.T.). European Heart Journal Supplements, 2017, 19, D113-D129.	0.0	30
77	Sacubitril/Valsartan Induces Global Cardiac Reverse Remodeling in Long-Lasting Heart Failure with Reduced Ejection Fraction: Standard and Advanced Echocardiographic Evidences. Journal of Clinical Medicine, 2020, 9, 906.	1.0	30
78	Exchange of β-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the) Tj ETQqC) 0 0 rgBT 2.9gBT	/Oyerlock 10
79	Predictors for Restoration of Normal Left Ventricular Function in Response to Cardiac Resynchronization Therapy Measured at Time of Implantation. American Journal of Cardiology, 2011, 108, 75-80.	0.7	29
80	Whole Exome Sequencing Identifies a Troponin T Mutation Hot Spot in Familial Dilated Cardiomyopathy. PLoS ONE, 2013, 8, e78104.	1.1	29
81	Chronic renal dysfunction and anaemia are associated with cognitive impairment in older patients with heart failure. Journal of Cardiovascular Medicine, 2014, 15, 481-490.	0.6	29
82	Renal Function and Peak Exercise Oxygen Consumption in Chronic Heart Failure With Reduced Left Ventricular Ejection Fraction. Circulation Journal, 2015, 79, 583-591.	0.7	29
83	Predictors of early-stage left ventricular dysfunction in type 2 diabetes: results of DYDA study. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 415-423.	3.1	28
84	Analysis of midwall shortening reveals high prevalence of left ventricular myocardial dysfunction in patients with diabetes mellitus: the DYDA study. European Journal of Preventive Cardiology, 2012, 19, 935-943.	0.8	28
85	The perioperative dental screening and management of patients undergoing cardiothoracic, vascular surgery and other cardiovascular invasive procedures: A systematic review. European Journal of Preventive Cardiology, 2017, 24, 409-425.	0.8	28
86	Prognostic role of βâ€blocker selectivity and dosage regimens in heart failure patients. Insights from the <scp>MECKI</scp> score database. European Journal of Heart Failure, 2017, 19, 904-914.	2.9	28
87	Management of atrial fibrillation in the emergency room and in the cardiology ward: the BLITZ AF study. Europace, 2019, 21, 230-238.	0.7	27
88	Impact of Atrial Fibrillation on Outcome of Patients with Idiopathic Dilated Cardiomyopathy: Data from the Heart Muscle Disease Registry of Trieste. Clinical Medicine and Research, 2010, 8, 142-149.	0.4	26
89	ANMCO Position Paper: hospital discharge planning: recommendations and standards. European Heart Journal Supplements, 2017, 19, D244-D255.	0.0	26
90	Programme to improve the use of beta-blockers for heart failure in the elderly and in those with severe symptoms: Results of the BRING-UP 2 Study. European Journal of Heart Failure, 2006, 8, 649-657.	2.9	25

#	Article	IF	CITATIONS
91	Severe heart failure prognosis evaluation for transplant selection in the era of beta-blockers: Role of peak oxygen consumption. International Journal of Cardiology, 2013, 168, 5078-5081.	0.8	25
92	Predictive role of CHA ₂ DS ₂ -VASc score for cardiovascular events and death in patients with arterial hypertension and stable sinus rhythm. European Journal of Preventive Cardiology, 2017, 24, 1584-1593.	0.8	25
93	Current management and treatment of patients with stable coronary artery diseases presenting to cardiologists in different clinical contexts: A prospective, observational, nationwide study. European Journal of Preventive Cardiology, 2018, 25, 43-53.	0.8	25
94	Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. European Heart Journal Supplements, 2018, 20, F1-F74.	0.0	25
95	Should we fear direct oral anticoagulants more than vitamin K antagonists in simple single tooth extraction? A prospective comparative study. Clinical Oral Investigations, 2019, 23, 3183-3192.	1.4	25
96	Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and midâ€range ejection fraction. European Journal of Heart Failure, 2019, 21, 1586-1595.	2.9	24
97	Idiopathic dilated cardiomyopathy and persistent viral infection: Lack of association in a controlled study using a quantitative assay. Heart Lung and Circulation, 2012, 21, 787-793.	0.2	23
98	Treatment with inotropes and related prognosis in acute heart failure: Contemporary data from the Italian Network on Heart Failure (IN-HF) Outcome registry. Journal of Heart and Lung Transplantation, 2014, 33, 1056-1065.	0.3	23
99	Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction. ESC Heart Failure, 2020, 7, 368-377.	1.4	23
100	Correlation between histomorphometric findings on endomyocardial biopsy and clinical findings in idiopathic dilated cardiomyopathy. American Journal of Cardiology, 1989, 64, 504-506.	0.7	22
101	ANMCO/AIOM/AICO Consensus Document on clinical and management pathways of cardio-oncology: executive summary. European Heart Journal Supplements, 2017, 19, D370-D379.	0.0	22
102	Recent trends in management and outcome of patients with acute coronary syndromes and atrial fibrillation. International Journal of Cardiology, 2017, 248, 369-375.	0.8	22
103	Exercise Performance Is a Prognostic Indicator in Elderly Patients With Chronic Heart Failure – Application of Metabolic Exercise Cardiac Kidney Indexes Score –. Circulation Journal, 2015, 79, 2608-2615.	0.7	21
104	Prognostic Role of Subclinical Left Ventricular Systolic Dysfunction Evaluated by Speckle-Tracking Echocardiography in Rheumatoid Arthritis. Journal of the American Society of Echocardiography, 2017, 30, 602-611.	1.2	21
105	Multi-state modelling of heart failure care path: A population-based investigation from Italy. PLoS ONE, 2017, 12, e0179176.	1.1	21
106	Clinical features, and in-hospital and 1-year mortalities of patients with acute heart failure and severe renal dysfunction. Data from the Italian Registry IN-HF Outcome. International Journal of Cardiology, 2013, 168, 3691-3697.	0.8	20
107	Atrial fibrillation, cognitive impairment, frailty and disability in older heart failure patients. Journal of Cardiovascular Medicine, 2016, 17, 616-623.	0.6	20
108	A new integrated approach to cardiac mechanics: reference values for normal left ventricle. International Journal of Cardiovascular Imaging, 2020, 36, 2173-2185.	0.7	20

#	Article	IF	CITATIONS
109	Left Atrial Work in Patients with Stable Chronic Heart Failure: Factors Associated and Prognostic Role. Echocardiography, 2014, 31, 123-132.	0.3	19
110	Personalized support for chronic conditions. Applied Clinical Informatics, 2016, 07, 633-645.	0.8	19
111	Sex Profile and Risk Assessment With Cardiopulmonary Exercise Testing in Heart Failure: Propensity Score Matching for Sex Selection Bias. Canadian Journal of Cardiology, 2016, 32, 754-759.	0.8	19
112	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic–therapeutic pathway in Italy. European Heart Journal Supplements, 2017, 19, D3-D54.	0.0	19
113	Prevalence and prognostic role of anaemia in patients with acute heart failure and preserved or depressed ventricular function. Internal and Emergency Medicine, 2013, 8, 147-155.	1.0	18
114	Contemporary management of patients referring to cardiologists one to three years from a myocardial infarction: The EYESHOT Post-MI study. International Journal of Cardiology, 2018, 273, 8-14.	0.8	18
115	Inappropriately high left ventricular mass in patients with type 2 diabetes mellitus and no overt cardiac disease. The DYDA study. Journal of Hypertension, 2011, 29, 1994-2003.	0.3	17
116	Cardiac calcification at transthoracic echocardiography predicts stress echo results: A multicentre study. International Journal of Cardiology, 2014, 174, 393-395.	0.8	17
117	Combined Circumferential and Longitudinal Left Ventricular Systolic Dysfunction in Patients with Rheumatoid Arthritis without Overt Cardiac Disease. Journal of the American Society of Echocardiography, 2016, 29, 689-698.	1.2	17
118	Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of) Tj ETQq0 0 0 r Cardiovascular Medicine, 2007, 8, 683-691.	rgBT /Over 0.6	lock 10 Tf 50 16
119	The progression of left ventricular systolic and diastolic dysfunctions in hypertrophic cardiomyopathy: clinical and prognostic significance. Journal of Cardiovascular Medicine, 2010, 11, 669-677.	0.6	16
120	Prognostic role of atrial fibrillation in patients affected by chronic heart failure. Data from the MECKI score research group. European Journal of Internal Medicine, 2015, 26, 515-520.	1.0	16
121	Improving the appropriateness of sudden arrhythmic death primary prevention by implantable cardioverter-defibrillator therapy in patients with low left ventricular ejection fraction. Point of view. Journal of Cardiovascular Medicine, 2016, 17, 245-255.	0.6	16
122	Prognostic role of cardiac calcifications in primary prevention: A powerful marker of adverse outcome highly dependent on underlying cardiac rhythm. International Journal of Cardiology, 2018, 258, 262-268.	0.8	16
123	Left ventricular dysfunction and outcome at two-year follow-up in patients with type 2 diabetes: The DYDA study. Diabetes Research and Clinical Practice, 2013, 101, 236-242.	1.1	15
124	Prevalence and factors related to inappropriately high left ventricular mass in patients with rheumatoid arthritis without overt cardiac disease. Journal of Hypertension, 2015, 33, 2141-2149.	0.3	15
125	Incremental prognostic value of restrictive filling pattern in hypertrophic cardiomyopathy: A Doppler echocardiographic study. European Journal of Echocardiography, 2007, 9, 466-71.	2.3	14
126	Rationale for cardiopulmonary exercise test in the assessment of surgical risk. Journal of Cardiovascular Medicine, 2013, 14, 254-261.	0.6	14

#	Article	IF	CITATIONS
127	Comparison of Patient Characteristics and Course of Hypertensive Hypokinetic Cardiomyopathy Versus Idiopathic Dilated Cardiomyopathy. American Journal of Cardiology, 2017, 119, 483-489.	0.7	14
128	Persistence on apixaban in atrial fibrillation patients: a retrospective multicentre study. Journal of Cardiovascular Medicine, 2019, 20, 66-73.	0.6	14
129	The role of implantable cardioverter defibrillator for primary vs secondary prevention of sudden death in patients with idiopathic dilated cardiomyopathy. Europace, 2004, 6, 400-406.	0.7	13
130	Clinical implications of the CKD epidemiology collaboration (CKD-EPI) equation compared with the modification of diet in renal disease (MDRD) study equation for the estimation of renal dysfunction in patients with cardiovascular disease. Internal and Emergency Medicine, 2015, 10, 955-963.	1.0	13
131	Mineralocorticoid receptor antagonists for heart failure: a realâ€life observational study. ESC Heart Failure, 2018, 5, 267-274.	1.4	13
132	Dose-dependent efficacy of Î ² -blocker in patients with chronic heart failure and atrial fibrillation. International Journal of Cardiology, 2018, 273, 141-146.	0.8	13
133	Cardiac imaging in patients with acute or chronic heart failure. Minerva Cardiology and Angiology, 2017, 65, 589-600.	0.4	13
134	Prognostic Stratification by Conventional Echocardiography of Patients with Aortic Stenosis: The "CAIMANâ€ECHO Score― Echocardiography, 2013, 30, 367-377.	0.3	12
135	ANMCO/SIC Consensus Document: cardiology networks for outpatient heart failure care. European Heart Journal Supplements, 2017, 19, D89-D101.	0.0	12
136	Adherence to Disease-Modifying Therapy in Patients Hospitalized for HF: Findings from a Community-Based Study. American Journal of Cardiovascular Drugs, 2020, 20, 179-190.	1.0	12
137	A Description of the Clinical Characteristics at Baseline of Patients Recruited into the Carvedilol or Metoprolol European Trial (COMET). Cardiovascular Drugs and Therapy, 2004, 18, 139-152.	1.3	11
138	The evolving care of the elderly with heart failure: from the â€~high-tech' to the â€~high-touch' approach. Journal of Cardiovascular Medicine, 2006, 7, 841-846.	0.6	11
139	Systolic blood pressure target in systemic arterial hypertension: Is lower ever better? Results from a community-based Caucasian cohort. European Journal of Internal Medicine, 2018, 48, 57-63.	1.0	11
140	Major bleeding with old and novel oral anticoagulants: How to manage it. Focus on reversal agents. International Journal of Cardiology, 2018, 268, 75-79.	0.8	11
141	Trend in potassium intake and Na/K ratio in the Italian adult population between the 2008 and 2018 CUORE project surveys. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 814-826.	1.1	11
142	Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO). Journal of Clinical Medicine, 2021, 10, 4185.	1.0	11
143	Antithrombotic management of patients with acute coronary syndrome and atrial fibrillation undergoing coronary stenting: a prospective, observational, nationwide study. BMJ Open, 2020, 10, e041044.	0.8	11
144	The challenge of cardiomyopathies in 2007. Journal of Cardiovascular Medicine, 2008, 9, 545-554.	0.6	10

#	Article	IF	CITATIONS
145	Oral anticoagulation and VKORC1 polymorphism in patients with a mechanical heart prosthesis: a 6-year follow-up. Journal of Thrombosis and Thrombolysis, 2012, 34, 506-512.	1.0	10
146	Chronic kidney disease and prognosis in elderly patients with cardiovascular disease: Comparison between CKD-EPI and Berlin Initiative Study-1 formulas. European Journal of Preventive Cardiology, 2016, 23, 1504-1513.	0.8	10
147	Characterization and Long-Term Prognosis of Postmyocarditic Dilated Cardiomyopathy Compared With Idiopathic Dilated Cardiomyopathy. American Journal of Cardiology, 2016, 118, 895-900.	0.7	10
148	Three dimensional printing of an atrial septal defect: Is it multimodality imaging?. International Journal of Cardiovascular Imaging, 2016, 32, 427-428.	0.7	10
149	Sex-related differences in chronic heart failure: a community-based study. Journal of Cardiovascular Medicine, 2021, 22, 36-44.	0.6	10
150	Updated clinical evidence and place in therapy of bempedoic acid for hypercholesterolemia: ANMCO position paper. Journal of Cardiovascular Medicine, 2021, 22, 162-171.	0.6	10
151	Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure. Journal of Cardiovascular Medicine, 2007, 8, 675-682.	0.6	9
152	HF progression among outpatients with HF in a community setting. International Journal of Cardiology, 2019, 277, 140-146.	0.8	9
153	Trends in management and outcome of patients with non-ST elevation acute coronary syndromes and peripheral arterial disease. European Journal of Internal Medicine, 2019, 59, 70-76.	1.0	9
154	Prevalence and Predictors of Out-of-Target LDL Cholesterol 1 to 3 Years After Myocardial Infarction. A Subanalysis From the EYESHOT Post-MI Registry. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 149-157.	1.0	9
155	Nonpredictive value of fibrosis in dilated cardiomyopathy treated with metoprolol. Cardiovascular Pathology, 1996, 5, 21-28.	0.7	8
156	Combined Circumferential and Longitudinal Left Ventricular Systolic Dysfunction in Patients with Asymptomatic Aortic Stenosis. Echocardiography, 2015, 32, 1064-1072.	0.3	8
157	Characteristics, treatment and quality of life of stable coronary artery disease patients with or without angina: Insights from the START study. PLoS ONE, 2018, 13, e0199770.	1.1	8
158	ls percutaneous coronary intervention safe during uninterrupted direct oral anticoagulant therapy in patients with atrial fibrillation and acute coronary syndromes?. Open Heart, 2021, 8, e001677.	0.9	8
159	Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test. Journal of Cardiac Failure, 2020, 26, 932-943.	0.7	8
160	Deleterious impact of mild anemia on survival of young adult patients (age 45 ± 14 years) with idiopathic dilated cardiomyopathy: Data from the Trieste Cardiomyopathies Registry. Heart and Lung: Journal of Acute and Critical Care, 2011, 40, 454-461.	0.8	7
161	Prevalence and Factors Associated with Subclinical Left Ventricular Systolic Dysfunction Evaluated by Midâ€Wall Mechanics in Rheumatoid Arthritis. Echocardiography, 2016, 33, 1290-1299.	0.3	7
162	ANMCO-SIMEU Consensus Document: in-hospital management of patients presenting with chest pain. European Heart Journal Supplements, 2017, 19, D212-D228.	0.0	7

#	Article	IF	CITATIONS
163	Prevalence and pharmacologic management of familial hypercholesterolemia in an unselected contemporary cohort of patients with stable coronary artery disease. Clinical Cardiology, 2018, 41, 1075-1083.	0.7	7
164	Early occurrence of drug intolerance as risk factor during follow-up in patients with acute coronary syndrome or coronary revascularization. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 195-201.	1.4	7
165	One-year clinical events and management of patients with atrial fibrillation hospitalized in cardiology centers: Data from the BLITZ-AF study. European Journal of Internal Medicine, 2020, 74, 55-60.	1.0	7
166	Post-discharge antithrombotic management and clinical outcomes of patients with new-onset or pre-existing atrial fibrillation and acute coronary syndromes undergoing coronary stenting: Follow-up data of the MATADOR-PCI study. European Journal of Internal Medicine, 2021, 88, 28-34.	1.0	7
167	Iodine Intake from Food and Iodized Salt as Related to Dietary Salt Consumption in the Italian Adult General Population. Nutrients, 2021, 13, 3486.	1.7	7
168	Long-term oral carvedilol in chronic heart failure. Expert Opinion on Pharmacotherapy, 2004, 5, 1359-1372.	0.9	6
169	Speeding up coeliac disease diagnosis in cardiological settings. Archives of Medical Science, 2010, 5, 728-732.	0.4	6
170	ANMCO Position Paper: direct oral anticoagulants for stroke prevention in atrial fibrillation: clinical scenarios and future perspectives. European Heart Journal Supplements, 2017, 19, D70-D88.	0.0	6
171	COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: insights from the START registry. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 513-520.	1.8	6
172	Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol in clinical practice: ANMCO position paper. Journal of Cardiovascular Medicine, 2021, 22, 609-617.	0.6	6
173	Major bleeding with old and novel oral anticoagulants: How to manage it. Focus on general measures. International Journal of Cardiology, 2018, 268, 80-84.	0.8	5
174	Administrative database, observational research and the Tower of Babel. International Journal of Cardiology, 2019, 284, 118-119.	0.8	5
175	Iodine Intake Estimated by 24 h Urine Collection in the Italian Adult Population: 2008–2012 Survey. Nutrients, 2021, 13, 1529.	1.7	5
176	Tafazzin Gene Mutations Are Uncommon Causes of Dilated Cardiomyopathy in Adults. Neurology International, 2011, 1, e4.	0.2	4
177	Does metabolic syndrome worsen systolic dysfunction in diabetes? The shortwave study. Acta Diabetologica, 2015, 52, 143-151.	1.2	4
178	Insights from Cardiac Mechanics after Three Decades from Successfully Repaired Aortic Coarctation. Congenital Heart Disease, 2016, 11, 254-261.	0.0	4
179	Tissue Doppler indices of diastolic function as prognosticator in patients without heart failure in primary care. Journal of Cardiology, 2020, 76, 18-24.	0.8	4
180	Combinations of antithrombotic therapies prescribed after percutaneous coronary intervention in patients with acute coronary syndromes and atrial fibrillation: data from the nationwide MATADOR-PCI registry. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e45-e47.	1.4	4

#	Article	IF	CITATIONS
181	Two-Dimensional Aortic Size Normalcy: A Novelty Detection Approach. Diagnostics, 2021, 11, 220.	1.3	4
182	The hemodynamic power of the heart differentiates normal from diseased right ventricles. Journal of Biomechanics, 2021, 119, 110312.	0.9	4
183	Risk stratification and secondary prevention post-myocardial infarction: insights from the EYESHOT Post-MI study. Journal of Cardiovascular Medicine, 2021, 22, 478-485.	0.6	4
184	Contemporary clinical management of acute pulmonary embolism: the COPE study. Internal and Emergency Medicine, 2022, 17, 715-723.	1.0	4
185	Do Pharmacological Differences Among Beta-Blockers Affect Their Clinical Efficacy in Heart Failure?. Cardiovascular Drugs and Therapy, 2004, 18, 91-93.	1.3	3
186	Reasons why patients suffering from chronic heart failure at very high risk for death survive. International Journal of Cardiology, 2014, 177, 213-218.	0.8	3
187	Radial pseudoaneurysm after a puncture for blood gas analysis. American Journal of Emergency Medicine, 2016, 34, 757.e1-757.e2.	0.7	3
188	Does treatment assignment influence the prognosis of patients with symptomatic severe aortic stenosis?. Cardiovascular Ultrasound, 2015, 13, 2.	0.5	2
189	Reasons why patients suffering from chronic heart failure at very low risk for mortality die. International Journal of Cardiology, 2016, 223, 947-952.	0.8	2
190	Are aortic coarctation and rheumatoid arthritis different models of aortic stiffness? Data from an echocardiographic study. Cardiovascular Ultrasound, 2018, 16, 9.	0.5	2
191	The challenge of heart failure diagnosis and management in primary care in elderly population: Mere illusion or concrete opportunity?. International Journal of Cardiology, 2019, 274, 248-249.	0.8	2
192	INtegration of care for reaching targetS In Diabetic patiEnts: Design of the INSIDE Study. Diabetes Therapy, 2020, 11, 359-367.	1.2	2
193	Indirect comparison between ferric carboxymaltose and oral iron replacement in heart failure with reduced ejection fraction: a network meta-analysis. Monaldi Archives for Chest Disease, 2021, 91, .	0.3	2
194	ANMCO POSITION PAPER: Use of sacubitril/valsartan in hospitalized patients with acute heart failure. European Heart Journal Supplements, 2021, 23, C176-C183.	0.0	2
195	Cardiac magnetic resonance in primary prevention of sudden cardiac death. Journal of Cardiovascular Echography, 2019, 29, 89.	0.1	2
196	Should beta-blocker therapy be reduced or withdrawn in patients with worsening heart failure? insights from COMET. Journal of Cardiac Failure, 2004, 10, S77.	0.7	1
197	Consistent survival benefit of carvedilol over metoprolol irrespective of baseline characteristics of heart failure patients – mode of death evaluation in COMET. Journal of Cardiac Failure, 2004, 10, S84.	0.7	1
198	Heart failure and sudden death in dilated cardiomyopathy: a hidden competition we should not forget about when modelling mortality. Journal of Evaluation in Clinical Practice, 2008, 14, 53-58.	0.9	1

#	Article	IF	CITATIONS
199	Analysis of Left Atrial Performance in Patients with Type 2 Diabetes Mellitus without Overt Cardiac Disease and Inducible Ischemia: High Prevalence of Increased Systolic Force Related to Enhanced Left Ventricular Systolic Longitudinal Function. Echocardiography, 2015, 32, 221-228.	0.3	1
200	Left ventricular function and exercise performance in idiopathic dilated cardiomyopathy. Journal of Cardiovascular Medicine, 2017, 18, 230-236.	0.6	1
201	ANMCO POSITION PAPER: Considerations on in-hospital cardiological consultations and cardiology outpatient clinics during the COVID-19 pandemic. European Heart Journal Supplements, 2020, 22, G228-G232.	0.0	1
202	ANMCO POSITION PAPER: The management of suspect or confirmed COVID-19 patients needing urgent electrophysiology and/or electrostimulation procedures. European Heart Journal Supplements, 2020, 22, G211-G216.	0.0	1
203	ANMCO POSITION PAPER: Network Organization for the Treatment of Acute Coronary Syndrome Patients during the Emergency COVID-19 Pandemic. European Heart Journal Supplements, 2020, 22, G223-G227.	0.0	1
204	ANMCO POSITION PAPER: Timing of coronary angiography in non-ST-segment elevation acute coronary syndromes. European Heart Journal Supplements, 2021, 23, C196-C203.	0.0	1
205	Impact on mortality of plasma NT-proBNP in chronic heart failure in patients treated with beta-blockers. results from COMET. Journal of Cardiac Failure, 2004, 10, S77.	0.7	0
206	Prognostic significance and the evolution of renal insufficiency in COMET trial. Journal of Cardiac Failure, 2004, 10, S78.	0.7	0
207	Clinical profile and outcome of anaemic patients with chronic heart failure in the COMET trial. Journal of Cardiac Failure, 2004, 10, S84.	0.7	0
208	Importance of atrial fibrillation in chronic heart failure in patients treated with β-blockers. results from COMET. Journal of Cardiac Failure, 2004, 10, S85.	0.7	0
209	PROGNOSTIC VALUE OF A SYSTEMATIC FAMILIAL SCREENING IN IDIOPATHIC DILATED CARDIOMYOPATHY. THE EXPERIENCE OF TRIESTE HEART MUSCLE DISEASE. Journal of the American College of Cardiology, 2010, 55, A131.E1223.	1.2	0
210	PROGNOSTIC STRATIFICATION OF BIOPSY-PROVEN ACTIVE MYOCARDITIS PRESENTING WITH HEART FAILURE: ARE THERE PREDICTORS OF LONG TERM PROGNOSIS?. Journal of the American College of Cardiology, 2010, 55, A27.E260.	1.2	0
211	Prognostic role of hemodynamic evaluation at rest and at maximum workload in patients with idiopathic dilated cardiomyopathy. International Journal of Cardiology, 2011, 150, 97-99.	0.8	0
212	Does renal function influence the prognostic impact of type 2 diabetes mellitus in patients with chronic heart failure and left ventricular dysfunction?. IJC Metabolic & Endocrine, 2014, 4, 53-57.	0.5	0
213	Echocardiographic markers of inducible myocardial ischemia at baseline evaluation preparatory to exercise stress echocardiography. Cardiovascular Ultrasound, 2015, 14, 21.	0.5	0
214	FP285WARFARIN TREATMENT: AN INDIPENDENT RISK FACTOR FOR RENAL EVENTS IN PATIENTS WITHOUT CKD. Nephrology Dialysis Transplantation, 2015, 30, iii163-iii163.	0.4	0
215	Galectin-3 and the Mineralocorticoid Receptor Antagonist Canrenone in Mild Heart Failure. Circulation Journal, 2017, 81, 1543-1546.	0.7	0
216	Response to: "Direct oral anticoagulants, vitamin K antagonists and simple single tooth extraction― Clinical Oral Investigations, 2019, 23, 1497-1498.	1.4	0

ANDREA DI LENARDA

#	Article	IF	CITATIONS
217	ANMCO POSITION PAPER: The role of cardiology in the management of the health needs in the post-Covid-19 era. European Heart Journal Supplements, 2020, 22, G217-G222.	0.0	0
218	ANMCO POSITION PAPER: The cardiological clinical activities in the transition phase of the COVID-19 pandemic. European Heart Journal Supplements, 2020, 22, G233-G238.	0.0	0
219	ANMCO POSITION PAPER: The reorganization of cardiology in times of the SARS-CoV-2 pandemic. European Heart Journal Supplements, 2021, 23, C154-C163.	0.0	0
220	Integrating Care in Complex Cardiac Care: the Tech Touch. International Journal of Integrated Care, 2016, 16, 383.	0.1	0